Provided by Tiger Trade Technology Pte. Ltd.

Immunome Inc.

20.01
-0.8200-3.94%
Post-market: 20.940.9300+4.65%18:45 EDT
Volume:5.73M
Turnover:115.44M
Market Cap:2.26B
PE:-8.23
High:21.26
Open:20.81
Low:20.01
Close:20.83
52wk High:27.65
52wk Low:5.15
Shares:113.00M
Float Shares:93.80M
Volume Ratio:5.49
T/O Rate:6.11%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.4315
EPS(LYR):-2.4315
ROE:-52.09%
ROA:-28.98%
PB:3.56
PE(LYR):-8.23

Loading ...

Immunome Grants Stock Options to New Employee Under 2024 Inducement Plan

Reuters
·
Feb 06

Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS
·
Feb 06

Immunome to Present at Guggenheim Emerging Outlook Biotech Summit

Reuters
·
Feb 04

Immunome (IMNM) Receives a Buy from Wedbush

TIPRANKS
·
Feb 04

Immunome Price Target Maintained With a $31.00/Share by Wedbush

Dow Jones
·
Jan 15

Wedbush Reaffirms Their Buy Rating on Immunome (IMNM)

TIPRANKS
·
Jan 15

Immunome Grants Stock Options to New Employees Under 2024 Inducement Plan

Reuters
·
Jan 09

Immunome Inc. CEO Clay B. Siegall Acquires Common Shares

Reuters
·
Dec 31, 2025

Immunome (IMNM): Assessing Valuation After Strong Phase 3 Varegacestat Data and $400 Million Equity Raise

Simply Wall St.
·
Dec 26, 2025

Immunome Inc. Director Isaac Barchas Reports Disposal of Common Shares

Reuters
·
Dec 24, 2025

Immunome CTO Philip Tsai Reports Acquisition of Common Shares

Reuters
·
Dec 22, 2025

Clay Siegall Bought 5.8% More Shares In Immunome

Simply Wall St.
·
Dec 20, 2025

Immunome CEO Clay B. Siegall Reports Acquisition of Common Shares

Reuters
·
Dec 19, 2025

BUZZ-U.S. STOCKS ON THE MOVE-Spotify, Robinhood Markets, Cannabis stocks

Reuters
·
Dec 17, 2025

BUZZ-U.S. STOCKS ON THE MOVE-Jabil, Texas Pacific Land, Texas Roadhouse

Reuters
·
Dec 17, 2025

BUZZ-Immunome slips after $400 mln stock sale

Reuters
·
Dec 17, 2025

Immunome Announces Pricing Of Public Offering Of 18,625,000 Shares At $21.50 Each

Reuters
·
Dec 17, 2025

Immunome Inc - Prices Public Offering of 18,625,000 Shares at $21.50 Each

THOMSON REUTERS
·
Dec 17, 2025

ADVISORY-Alert from Equity-Insider.com was published in error and has been withdrawn

Reuters
·
Dec 17, 2025

Cancer Drug Developers Secure Regulatory Clarity as FDA Reshapes Approval Standards

THOMSON REUTERS
·
Dec 17, 2025